Vanucizumab - Roche

Drug Profile

Vanucizumab - Roche

Alternative Names: RG-7221; RO-5520985

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 23 Oct 2017 Discontinued - Phase-II for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in Spain, France, Belgium, Austria, Australia, USA (IV) (Roche pipeline, October 2017)
  • 08 Oct 2017 Adverse events and efficacy data from a phase I trial in Solid tumours released by Roche
  • 03 Jun 2017 Final efficacy and adverse events data from a phase II McCAVE trial in Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top